|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,400 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: BRILINTA
Summary for Tradename: BRILINTA
|
| |||||||||
Clinical Trials for: BRILINTAStudy to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) Status: Completed Condition: Acute Coronary Syndrome; Percutaneous Coronary Intervention Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients Status: Recruiting Condition: Coronary Artery Disease Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects. Status: Completed Condition: Blood Flow Speed; Coronary Flow Velocity Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG Status: Recruiting Condition: Coronary Artery Desease,; Stable Angina,; Acute Coronary Syndrome Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients Status: Not yet recruiting Condition: Type-2 Diabetes Mellitus; Coronary Artery Disease A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders Status: Completed Condition: Stable Coronary Artery Disease PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males Status: Not yet recruiting Condition: Healthy Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) Status: Completed Condition: ST-elevation Myocardial Infarction Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel Status: Not yet recruiting Condition: Diabetes Mellitus; Coronary Disease Impact of Ticagrelor Re-load on Pharmacodynamic Profiles Status: Recruiting Condition: Coronary Artery Disease Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Lp | BRILINTA | ticagrelor | TABLET; ORAL | 022433 | Jul 20, 2011 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca Lp | BRILINTA | ticagrelor | TABLET; ORAL | 022433 | Jul 20, 2011 | RX | Yes | 6,251,910 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca Lp | BRILINTA | ticagrelor | TABLET; ORAL | 022433 | Jul 20, 2011 | RX | Yes | 6,525,060 | Y | Y | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca Lp | BRILINTA | ticagrelor | TABLET; ORAL | 022433 | Jul 20, 2011 | RX | Yes | 7,250,419 | Y | Y | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc
